Purple Biotech Ltd
PPBT
View Detailed Chart
0.571USD
+0.009+1.66%
Market hours （ET）Quotes delayed by 15 min
323.92MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+1.66%
5 Days
-59.82%
1 Month
-73.22%
6 Months
-78.99%
Year to Date
-87.84%
1 Year
-93.02%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated：2025-09-10Key Insights
The company's fundamentals are relatively weak. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company has shown average stock market performance, with mediocre fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
1
analysts
Buy
Current Rating
34.000
Target Price
+5958.45%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.
Fairly Valued
The company’s latest PE is -220.94, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 55.19K shares, decreasing 78.51% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 0.00 shares of this stock.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.
Ticker SymbolPPBT
CompanyPurple Biotech Ltd
CEOMr. Gil Efron, CPA
Websitehttps://purple-biotech.com/
Related Instruments
+0.18%
+3.57%
+7.01%
+3.55%
-0.18%
+3.37%
+13.25%
+4.42%
+5.42%
+5.60%
-0.50%
+2.15%
+3.57%
-5.66%
+0.23%
+0.14%
+1.84%
+14.39%
0.00%
+4.39%
